PharmaCyte Biotech Inc (PMCB)

[Mens et Manus]

Here is an example of two large Pharms doing a trial. Note only phase 1 and will take thru mid 2017:

Bristol-Myers Squibb and Celgene hope that adding Opdivo to that regimen could add additional months to survival, and the two companies are currently recruiting patients for a phase 1 safety study that will run until mid-2017. Although the primary goal of this study is to make sure that the combination is safe, the trial will also evaluate progression-free survival and overall survival.